INCIDENCE AND RISK FACTORS ASSOCIATED WITH THE DEVELOPMENT OF CYTOMEGALOVIRUS DISEASE
From May 1990 to March 1993.38 patients (21 adults and 17 children) received 40 allografts that included the small bowel (14 isolated small bowel. 21 small howel and liver. and 5 multivisceral transplantations). Fifteen patients 139%) had 26 episodes of CMV disease: 7 with one episode, 6 with two, and 1 each with three and four. CMV enteritis accounted for 21 (81%) of the episodes, hepatitis and pneumonitis for 2 each. and a viral syndrome for 1. Cox's proportional hazards univariate and multivariate analyses showed that signif-
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ieant first·episode risk factors were: CMV seropositive donors for negative recipients (relative risk (RRJ, 3.86; P=O.02), the average daily plasma trough level of tacrolimus IRK. 2.15; P=O.04). and total amount of steroid boluses 1 RR., 2.90; P=O.02) . CMV disease recurrence factors were: CMV seronegative recipients (RR, 8.60; P=0.02) and total amount of steroid bolus pu.laes (RR. 12.39; P=O.004). Because long COUJ'lle8 of l&Dciclo-vir prophyla.s:is could not prevent the development of CMV disease, avoidance of CMV seropositive tn.fta in seronegadve recipients and new strategies to prevent heavy immunosuppresaion without the penalty of rejection will be neceuary to ameliorate this problem in intestinal tran.plant recipients.
Cytomegalovirus is the moat common mfectious complication after organ transplantation. occumng m 6~ to 70,*, of kidney, liver. bone marrow. heart. and lung tranSplant reaptents \ 1-4). While the prevalence and tumng of CMV infec:-o\Drrl 15, 1995 ' ntera! feedmg, The oral and intravenous routes were overlapped for several days at the transition, Trough plasma levels of tacrolimus w .. re momtored dad\' With a target therapeutic level between 1 and \ n~/ml. In adult patients, methvlpredmsolone was started intraop' .'ratl\'t'ly with a I'I! holus followt'd b\' a sterOId taper from :l00 mg to ~lJ ml! o\'t'r ii davs, and maintained at or weaned thereafter from the dose of 20 mwda\', ('htldren were gwen 1 ~ of hydrocortIsone Intra· "pl'ratl\, .. lv, t'ollowl'd b\' methylpredmsolone, which was tapered over " days Irom !OO to Iii mwdav, Prostaglandin 1::1 was started intra-'llt'f:tt!\'l'l\' at a dose 01 02-0,6 mwkwhr and continued for 7 to 14 .t,IVS :-'un'Plllance enao~eopy With multlple mucosal blOpsle8 was ""ftorrnI'O once or tWice per wpek for the lirst J months. and when-, ' cpr It "';IS (IlmClIl\' Indlcatell therealter, The most severe acute :r:lIt n'll'Ctions ""'re treated either by uUI.[1'Tlt!ntlnf,( tacrollmus ther· 'P\', 1·1! "terold bolus 01 methvlpredmsolone In adults (or hydrocor· l"one 11\ children I, a S·dav sterOId burst. or a ii·dav course of OKT3 mAil \.~ I, Howl'vt'r, not all patients reqUired drastlc treatment. and : he rt'soonse to rPl"cllon was commensurate With Its seventy, rhlrl.· .. n patients I ,H', I received prophvlaxls With ganclclovir 10 "H!/kl!'dav lor 2 Wl'l'ks, followed by acyclOVir J200 mwday tadultsl or "110 mc'm-,I times u oav lchddrenl for ti months. In Il patients (:l1':'rl. ~:meld()\,lf prophvlaxlS was malntamed for.l months and followed bv 'Ilch Jnse IIcyclo\'lr untli ti months, £Ieven chddren ana 2 adults who ,\ pre \ '~\V ,;"ronef,(atlve received onlv C:'IV ·~eronegallve blood prod-;clS In aodlllOn to their C:.tv·negauve liver, I ',\1\' III ,i'CIW" "lin ",liance cuiturn ana definltlon o{ C.UV enter· ':, :-'p .. clmens I()r \ ~tv cultures and serolollY were obtAmed when-"'r ,ntectlon was ,-uspected clmlcall\', (,~IV cultures were per· ',' rml'O II\' the ,hell \'lal assav and standard culture techmque. "l'roioI!1Cal te~ts lor ('~fV were pert'onned bv a semlautomated 1m-'!1unollu()rt'scence I FIA.X) test In those patients who were CMV se-')n .. cutl\'e I n ~ patients. ~ Wlth ana 2 Wlthout c~tv infection.
l '\\\'·n:-':A W:llI mOnitored tn blood butTv coats ustnl( the polvrnerase ,num n'3ctJon \ PCR)' !('chmque.
,~vrnptomatlc C~IV injection wu defined by seroconvenllon or Statlstlcal analys",. Univanate and multlvanate analysIs of risk factors for the first episode and recurrent c~tv disease were done using the Cox proportional hazards model. Pretransplant donorrecipient serological status wa8 analyzed as Indicator vanabIe USinl!' negative donor/negative recIpIent as the reference category. The likelihood ratIo chi-square test was used to assess the nsk of each factor. Based on the results of these univariate analysis. a multiva· nate analysia wa8 performed. Variables were chosen to be included m the multivanate analyse8 If they had a P<O, 25 . The backward elimination method was used as a vanable selection technique USing the likelihood ratio chi-square test as means to assess each factor, Variables were entered or excluded from the model based on a P-value for entry of 0.10 and a P-value lor exclusion of 0.15. Approx· Imate 95% conlidence intervals (CIl were generated for each relative nsk (RR). The cumulative 1·year mortalltv was estimated USing the Kaplan-Maler method,
RESULTS
Incidence. tlmln~ dence of CMV disease among C~fV-seropositive recipients was 50%. regardless of whether the donor's serologic status was negative (418) or positive (214). Two (17%) of these 12 seropositive recipients had CMV disease recurrence after their first postoperative bout of disease. Nine (75%) of the high risk group of 12 seronegative recipIents who received seropositive grafts developed 18 episodes of CMV disease. Their 9 primary mfections and 9 recurrences accounted for 69% of the 26 disease episodes in the study, wlth an overwhelming incidence oi intestinal graft involvement. Of the 3 exceptional patients who escaped this complication. 2 died after 23 and 49 posttransplantation days, and the third was diagnosed of asymptomatic infection 103 days after transplantation.
When CMV disease was diagnosed. the first episode was treated with ganciclovir 10 mg/kglday for 21 days. The second episode was treated with either ganclcloVlr 10 mgtkg/day or foscarnet 180 mg/kg/day for 1 month. Recurrence after the second episode was treated with either ganclciovir 10 mg/kg/ day or foscarnet 180 mgtkglday for 3 months and a mamtenance dose of 5 mg/kg/day of ganclciovir or 90-120 mgtkg/day of foscarnet thereafter. All dosages of ganclcloVlr and foscarnet were adjusted for renal function. Four patients developed C~ disease recurrence during mamtenance ganclciovir therapy and were converted to foscarnet. When 2 of them recurred dunng maintenance Foscarnet. inductIOn doses of ganclciovlr and C\fV-speClfic hypenmmunglobuhn (100 mw kg/weekI were added to the foscarnet therapy, despite which 1 of the patients developed a new recurrence dunng the tnple therapy. This last patient was then gIVen mduction doses of ganclcioVlr and foscamet for 3 months. followed by maintenance doses of both antlvirals. No further episodes occurred dunng the subsequent 4 months.
Twenty-sIx (68%) of the 38 patients sUrVlved > 1 year. Of the 12 deaths. 7 were among the 15 patients (47%) in whom C~ disease developed. occumng 253= 131 days after transplantation. However. evidence of active CM\' disease at death and/or autopsy was present 10 only 1 pauent. Five patients (22%) who did not develop C~fV disease died at 105 = 141 days alter transplantauon (Fig. 11 
DISCUSSION
The hazard of CMV infection in recipients of whole organs and bone marrow has been noted almost from the beglnmng of successful clinical use of these procedures (9). Realization that the donor organ IS a frequent inoculation source (JO) as well as a vulnerable posttransplantatlon target, and recognition that C~{V disease frequency IS associated Wlth the intenSity of immunosuppression are common to all kinds of allograit recipients. The InfectiOUS syndromes resemble those found in pauents Wlth inherited (J 1) or virus-induced acqWred immune deficiency disorders (121.
The strong aSSOCiation between the development and/or recurrence of C~fV disease and the amount of both tacrolimua and steroid pulses was ex~ted. Both drop inhibit cell-mediated responsetl. through blockade of cytokine ex. presalon \13, 14 , D '!R -. donor positiVe/recIpIent negatIve.
portant in protection from progressive infection of the immu· nocompromlsed host (16) . is suppressed by high dose sterOId therapy, which decreases serum Immunoglobulin levels wIth .\ de laved maximal effect 2-4 weeks after treatment (Ii). I ;astrOlntestmal lesIOns that contain cytomelralic cells have heen reported m assoclatlon WIth sterOId therapy (18, 19) , prompting several authors to propOHe that sterOld·assoclated peptic ulcer disease may be, In iact. a CMV disease (20, 211. While the types of CMV infections In our intestinal reclplents have been slmIiar to those receIVIng other organs. the , ' pldemlOloglc pattern has been distmgulshed by a high inCIdence of infection and recurrence rates In the bowel allograft I tself. a 50% inCidence of CMV disease m patients who were ~erOpOSltI\'e before transplantation. less than 50% incidence [t was not pOSSible to rule out m these patients that the unusual Cl\iV protile herein reported was caused by ganci· clovir· or foscarnet·reslstant CMV strams (33), This was due to the difficulty in isolating the VlruS when the patients were receIving antIviral therapy loU). Althoulth sporadic spot checks 10 other kinds of organ reCIpIents failed to demonstrate antlVlral drug resIstance. this IS something that needs to be conSidered. partIcularly in those patients who receIve antIVlral therapy for long penods of time.
[nsight Into the spectacular ability of organs from CMV carrier.! to Infect recipients. or. conversely. of an infected recipient to infect a graft. haa come from recent discovery of the ubiqwtous mIgratIon of donor -passenger" leukocytes that beglns Within a few mmutes after graft revaacularizatlon t35-38). The mfectIous potential of these long-sW'Vlving chimenc cells is obvious. and presumably related. to the reiaUve cell doae sprayed into reclplent tissues from different transplanted organa pl"OCUred from carnera of CMV (and presumably some other VlruaeSJ. Because a long course of 1014 TRANSPLANTATION Vol. 59, No.7 currently available prophylaxis cannot prevent life-threatening CMV disease In the unusually vulnerable Cl\IV-negative Intestmal recIpient. avoidance of Cl\IV-seropositive grafts has overriding Importance. Approaches to prevent long-term. heavy immunosuppression are a possible future alternatIve. One such initiatIve may be to augment the spontaneous cell migration by admimstering C~IV-negatlve donor bone marrow before surgery. Although this strategy would have been considered heretical until recently, it has proved to be safe and effective wIth all other organs. including the leukocyterich liver \38L
